Search results
Showing 496 to 510 of 1044 results for criteria
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
High-intensity focused ultrasound for prostate cancer (IPG118)
Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.
Early value assessment (EVA) guidance on artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referra...
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)
Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
Lumbar infusion test for the investigation of normal pressure hydrocephalus (IPG263)
Evidence-based recommendations on the lumbar infusion test for the investigation of normal pressure hydrocephalus. This involves inserting a lumbar needle into the spinal sac, recording the pressure of the CSF as fluid is infused into the sac.
View recommendations for IPG263Show all sections
Sections for IPG263
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Evidence-based recommendations on percutaneous fetal balloon valvuloplasty for pulmonary atresia with intact ventricular septum. This involves opening up the closed pulmonary valve of the babies heart while it is still in the womb using a balloon-like device.
View recommendations for IPG176Show all sections
Sections for IPG176
Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (IPG202)
Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.
View recommendations for IPG202Show all sections
Sections for IPG202